Voriconazole treatment for less-common, emerging, or refractory fungal infections

John R. Perfect, Kieren Marr, Thomas J. Walsh, Richard N. Greenberg, Bertrand DuPont, Juliàn De La Torre-Cisneros, Gudrun Just-Nübling, Haran T. Schlamm, Irja Lutsar, Ana Espinel-Ingroff, Elizabeth Johnson

Research output: Contribution to journalArticle

Abstract

Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for

Original languageEnglish (US)
Pages (from-to)1122-1131
Number of pages10
JournalClinical Infectious Diseases
Volume36
Issue number9
DOIs
StatePublished - May 1 2003
Externally publishedYes

Fingerprint

Mycoses
Therapeutics
Infection
Fusariosis
Cryptococcosis
Salvage Therapy
Aspergillosis
Voriconazole
Candidiasis
Treatment Failure
Safety

ASJC Scopus subject areas

  • Immunology

Cite this

Perfect, J. R., Marr, K., Walsh, T. J., Greenberg, R. N., DuPont, B., De La Torre-Cisneros, J., ... Johnson, E. (2003). Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clinical Infectious Diseases, 36(9), 1122-1131. https://doi.org/10.1086/374557

Voriconazole treatment for less-common, emerging, or refractory fungal infections. / Perfect, John R.; Marr, Kieren; Walsh, Thomas J.; Greenberg, Richard N.; DuPont, Bertrand; De La Torre-Cisneros, Juliàn; Just-Nübling, Gudrun; Schlamm, Haran T.; Lutsar, Irja; Espinel-Ingroff, Ana; Johnson, Elizabeth.

In: Clinical Infectious Diseases, Vol. 36, No. 9, 01.05.2003, p. 1122-1131.

Research output: Contribution to journalArticle

Perfect, JR, Marr, K, Walsh, TJ, Greenberg, RN, DuPont, B, De La Torre-Cisneros, J, Just-Nübling, G, Schlamm, HT, Lutsar, I, Espinel-Ingroff, A & Johnson, E 2003, 'Voriconazole treatment for less-common, emerging, or refractory fungal infections', Clinical Infectious Diseases, vol. 36, no. 9, pp. 1122-1131. https://doi.org/10.1086/374557
Perfect JR, Marr K, Walsh TJ, Greenberg RN, DuPont B, De La Torre-Cisneros J et al. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clinical Infectious Diseases. 2003 May 1;36(9):1122-1131. https://doi.org/10.1086/374557
Perfect, John R. ; Marr, Kieren ; Walsh, Thomas J. ; Greenberg, Richard N. ; DuPont, Bertrand ; De La Torre-Cisneros, Juliàn ; Just-Nübling, Gudrun ; Schlamm, Haran T. ; Lutsar, Irja ; Espinel-Ingroff, Ana ; Johnson, Elizabeth. / Voriconazole treatment for less-common, emerging, or refractory fungal infections. In: Clinical Infectious Diseases. 2003 ; Vol. 36, No. 9. pp. 1122-1131.
@article{5d484d8a7b8e46518998e182a8c0768c,
title = "Voriconazole treatment for less-common, emerging, or refractory fungal infections",
abstract = "Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50{\%} of the overall cohort; specifically, successful outcomes were observed in 47{\%} of patients whose infections failed to respond to previous antifungal therapy and in 68{\%} of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7{\%} for aspergillosis, 57.5{\%} for candidiasis, 38.9{\%} for cryptococcosis, 45.5{\%} for fusariosis, and 30{\%} for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for",
author = "Perfect, {John R.} and Kieren Marr and Walsh, {Thomas J.} and Greenberg, {Richard N.} and Bertrand DuPont and {De La Torre-Cisneros}, Juli{\`a}n and Gudrun Just-N{\"u}bling and Schlamm, {Haran T.} and Irja Lutsar and Ana Espinel-Ingroff and Elizabeth Johnson",
year = "2003",
month = "5",
day = "1",
doi = "10.1086/374557",
language = "English (US)",
volume = "36",
pages = "1122--1131",
journal = "Clinical Infectious Diseases",
issn = "1058-4838",
publisher = "Oxford University Press",
number = "9",

}

TY - JOUR

T1 - Voriconazole treatment for less-common, emerging, or refractory fungal infections

AU - Perfect, John R.

AU - Marr, Kieren

AU - Walsh, Thomas J.

AU - Greenberg, Richard N.

AU - DuPont, Bertrand

AU - De La Torre-Cisneros, Juliàn

AU - Just-Nübling, Gudrun

AU - Schlamm, Haran T.

AU - Lutsar, Irja

AU - Espinel-Ingroff, Ana

AU - Johnson, Elizabeth

PY - 2003/5/1

Y1 - 2003/5/1

N2 - Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for

AB - Treatments for invasive fungal infections remain unsatisfactory. We evaluated the efficacy, tolerability, and safety of voriconazole as salvage treatment for 273 patients with refractory and intolerant-to-treatment fungal infections and as primary treatment for 28 patients with infections for which there is no approved therapy. Voriconazole was associated with satisfactory global responses in 50% of the overall cohort; specifically, successful outcomes were observed in 47% of patients whose infections failed to respond to previous antifungal therapy and in 68% of patients whose infections have no approved antifungal therapy. In this population at high risk for treatment failure, the efficacy rates for voriconazole were 43.7% for aspergillosis, 57.5% for candidiasis, 38.9% for cryptococcosis, 45.5% for fusariosis, and 30% for scedosporiosis. Voriconazole was well tolerated, and treatment-related discontinuations of therapy or dose reductions occurred for

UR - http://www.scopus.com/inward/record.url?scp=0038556830&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0038556830&partnerID=8YFLogxK

U2 - 10.1086/374557

DO - 10.1086/374557

M3 - Article

C2 - 12715306

AN - SCOPUS:0038556830

VL - 36

SP - 1122

EP - 1131

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

SN - 1058-4838

IS - 9

ER -